Fosun Pharma tests wearable AI health devices with 1 million yuan unit

Fosun Pharma has set up a 1 million yuan (about $140,000) unit to sell wearable smart devices and AI hardware, a low-cost test of out-of-hospital health management as its core diagnostics business comes under pricing pressure.

The new entity, Shanghai Fuzhenkang Biotechnology, was recently incorporated with Zhang Haitao as legal representative, according to corporate records database Tianyancha. The registered capital is small next to the tens of billions of yuan the group spends on drug research, but the ownership structure shows how Fosun intends to tie partners to the venture.

Ownership and control

Fosun Diagnostics holds 80%. Guangzhou Xingzhijian Health Management and Guangzhou Xingxiangjian Enterprise Management Partnership (LP) each hold 10%, the records show. Fosun Diagnostics is a wholly owned subsidiary of Fosun Pharma, which is listed in both Shanghai and Hong Kong.

Zhang, a core figure at Fosun Diagnostics, takes the legal representative role himself. The 80% stake keeps the business consolidated within Fosun, while the two 10% holders give the operating team and outside partners a share of the upside, according to the registration.

An IVD veteran moves into consumer hardware

The approved business scope is the striking part. Alongside conventional health consulting and new-material research, it lists sales of wearable smart devices and AI hardware.

Fosun Diagnostics built its business on hospital laboratories: biochemical reagents, chemiluminescence and molecular diagnostic instruments. The move into consumer-facing hardware reflects the pressure on that model.

Centralized procurement, now spreading across IVD products, along with medical insurance cost controls and the separation of service fees from consumables, has ended hospitals' reliance on high-margin reagents. Diagnostic companies face compressed factory prices, longer payment cycles and tougher approval for equipment entering hospitals.

Outside the hospital, chronic disease management, home health monitoring and anti-aging products are creating large new pools of self-paid demand.

Consumer wearables have long been limited by their toy-like status: they count steps and measure heart rate, but the data lacks clinical rigor and cannot connect to the medical system.

Fosun Diagnostics aims to change that by applying clinical algorithms and biomarker logic to consumer devices. The plan is to combine miniature biochemical sensors and continuous monitoring algorithms with wearables, bringing hospital-grade diagnostics into the home. Examples include continuous glucose monitoring (CGM), wearable ECG patches and multi-parameter biochemical analyzers paired with AI agents that produce structured health reports.

Inside the Fosun ecosystem

The deeper motive is to link the venture to Fosun Pharma's wider healthcare network. Unlike a standalone hardware startup, Fosun has its own hospitals across the country, an insurance arm in Fosun United Health Insurance and a large portfolio of chronic-disease prescription drugs.

If a user's wearable flags an abnormal reading, the data can be routed to Fosun's online consultation platforms and partner clinics, or matched to commercial health insurance underwriting and specialty drug coverage.

That combination of hardware touchpoint, medical service delivery and insurance backstop is a moat pure hardware makers cannot copy, according to the company's positioning.

A signal, and a hard test

The 1 million yuan outlay sends a clear signal: a serious medical group is testing out-of-hospital health management in an asset-light way, capping the cost of failure.

But consumer wearables are dominated by Huawei, Apple and other electronics giants with deep ecosystems. Whether Fosun Diagnostics can turn its medical expertise into a self-sustaining hardware-and-software business is the question the new company must now answer.